An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer
- 31 March 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (7), 2707-2717
- https://doi.org/10.1158/0008-5472.can-09-4299
Abstract
The diversity and extent of the local tumor-specific T-cell response in a given individual is largely unknown. We have performed an in-depth study of the local T-cell repertoire in a selected group of patients with cervical cancer, by systematic analyses of the proportion, breadth, and polarization of human papillomavirus (HPV) E6/E7-specific T cells within the total population of tumor-infiltrating lymphocytes (TIL) and tumor-draining lymph node cells (TDLNC). Isolated T cells were stimulated with sets of overlapping E6 and E7 peptides and analyzed by multiparameter flow cytometry with respect to activation, cytokine production, and T-cell receptor Vbeta usage. HPV-specific CD4+ and CD8+ T-cell responses were detected in TIL and TDLNC and their relative contribution varied between <1% and 66% of all T cells. In general, these HPV-specific responses were surprisingly broad, aimed at multiple E6 and E7 epitopes and involved multiple dominant and subdominant T-cell receptor Vbetas per single peptide-epitope. In most patients, only few IFNgamma-producing T cells were found and the amount of IFNgamma produced was low, suggesting that these are poised T cells, rendered functionally inactive within the tumor environment. Importantly, stimulation of the TIL and TDLNC with cognate antigen in the presence of commonly used Toll-like receptor ligands significantly enhanced the effector T-cell function. In conclusion, our study suggests that within a given patient with HPV-specific immunity many different tumor-specific CD4+ and CD8+ T cells are locally present and poised for action. This vast existing local T-cell population is awaiting proper stimulation and can be exploited for the immunotherapy of cancer.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitProceedings of the National Academy of Sciences, 2008
- Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell ResponseClinical Cancer Research, 2008
- Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificitiesCytometry Part A, 2008
- Engagement of Toll‐like receptor‐2 on cytotoxic T‐lymphocytes occursin vivoand augments antitumor activityThe FASEB Journal, 2008
- CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer TherapyJournal of Immunotherapy, 2008
- Memory T Cells Specific for Novel Human Papillomavirus Type 16 (HPV16) E6 Epitopes in Women Whose HPV16 Infection Has Become UndetectableClinical and Vaccine Immunology, 2008
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose TrialJournal of Virology, 2008
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides VaccineClinical Cancer Research, 2008
- Association of cervical cancer with the presence of CD4+regulatory T cells specific for human papillomavirus antigensProceedings of the National Academy of Sciences, 2007
- Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patientsZeitschrift für Krebsforschung und Klinische Onkologie, 2003